Anasmol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anasmol

Property Description
Active ingredient Warfarin Sodium
Form Oral Tablet
Pharmacological Class Anticoagulant, Vitamin K Antagonist (VKA)
General Purpose To prevent the formation of harmful blood clots
Origin Synthetic chemical (Coumarin derivative)

1. Identity and Composition: What is the Drug Anasmol?

Anasmol is the trade name for the active drug Warfarin Sodium, which is formulated as an oral tablet for systemic administration. This single-ingredient product is based on the synthetic chemical warfarin, a Coumarin derivative. The active compound is supplied as a racemic mixture of R- and S-enantiomers. The S-enantiomer is more potent in its anticoagulant effect than the R-isomer.

2. Pharmacological Class: Warfarin Sodium as an Anticoagulant

Anasmol is classified within the therapeutic group of Anticoagulants, commonly referred to as blood thinners, and is specifically defined as a Vitamin K Antagonist (VKA). Its core action is the inhibition of the enzyme Vitamin K epoxide reductase (VKOR) in the liver. This mechanism reduces the body’s synthesis of functional clotting factors (II, VII, IX, X).

3. General Purpose: Why is Anasmol Used as a Blood Thinner?

The primary purpose of Anasmol is to provide maintenance therapy that interferes with the blood's clotting cascade. This action is designed to reduce the risk of clot formation, such as in patients requiring long-term management of circulatory conditions. By lowering the blood's capacity to solidify, this oral anticoagulant promotes steady, long-term blood flow.

Regulatory References

  1. Warfarin - StatPearls - NCBI Bookshelf

What side effects are possible with Anasmol?

Possible Side Effects and Safety Information

The safety profile of Anasmol (Warfarin Sodium) is officially defined by its primary action as an anticoagulant, with the principal safety concern being the potential for hemorrhage (bleeding).

Official Adverse Reaction Classification

According to government regulatory documents, hemorrhage is classified as a Very Common adverse reaction. Other documented effects are categorized by frequency and the physiological system affected:

  • Common Reactions: These can include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as headache and dizziness.
  • Uncommon Reactions: These reactions, occurring less frequently, include hair loss (alopecia), rashes, pruritus, fatigue, and fever.
  • Rare Reactions: These are infrequent but officially documented, including severe hypersensitivity reactions, cholestasis, and reversible liver injury.

System-Organ Classes and Serious Events

Adverse reactions are formally grouped into System-Organ Classes (SOCs), with the most important being Blood and lymphatic system disorders (hemorrhage). Other SOCs include Gastrointestinal, Hepatobiliary, and Skin disorders (which can include Warfarin-induced skin necrosis).

Serious Adverse Reactions officially listed in regulatory texts include major or life-threatening hemorrhage, such as intracranial or retroperitoneal bleeding, and the rare but severe event of Warfarin-induced skin necrosis.

Population-Specific Safety Notes

The regulatory safety profile notes specific considerations for certain patient groups. Older adults are documented as having an increased risk of major and fatal bleeding events. Furthermore, caution is noted for individuals with severe hepatic or renal impairment due to the associated increase in bleeding risk. Official labels restrict or contraindicate the use of Anasmol in situations where the risk of hemorrhage significantly outweighs the clinical benefit.

Overdose and Emergency Response

Anasmol Overdose and When to Seek Help

The most serious consequence of Anasmol (Warfarin Sodium) overdose is major or fatal hemorrhage (bleeding) from any organ or tissue. Overdose is characterized by a state of supratherapeutic anticoagulation, indicated by an International Normalized Ratio (INR elevated beyond 4.0).

Regulatory documents list specific signs of bleeding that require immediate reporting: bloody or red or tarry bowel movements, vomiting material that resembles coffee grounds, uncontrolled bleeding from cuts, unusual bruising, and nosebleeds. Potential severe outcomes include tissue necrosis or gangrene, acute kidney injury, and systemic emboli.

When to Seek Urgent Medical Help

Immediate medical attention must be sought, and emergency services (911) should be contacted, if an individual experiences severe symptoms such as collapse, seizure, trouble breathing, or inability to be awakened. Additionally, patients must be instructed to report all signs and symptoms of bleeding immediately to a physician.

The official management protocol involves immediately stopping the medication and administering Vitamin K as the reversal agent, which is the specific antidote for excessive anticoagulation. For major bleeding, procedures may include replacement of clotting factors using products like Fresh Frozen Plasma. Close serial INR monitoring for up to 48 hours is a documented requirement in overdose situations. Regulatory guidance also notes that geriatric patients (age 60 and older) and those with hepatic or renal insufficiency have an increased risk of bleeding complications.

Therapeutic Uses of Anasmol

Anasmol (a medication used to help manage conditions linked to blood clot risk) generally provides supportive therapeutic benefit by helping to moderate distressing symptoms associated with blood clot formation risk and related conditions. It is applied across domains where additional symptomatic support is needed. Its use includes conditions such as atrial fibrillation, the presence of a mechanical heart valve, and the management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

Supporting Symptomatic Stability

This medication is commonly used across conditions presenting with acute episodes as well as chronic risk scenarios. It is applied in clinical settings that involve acute or unstable symptom patterns, where it assists with supporting functional stability and managing symptoms that create noticeable physiological strain. This therapy assists in addressing symptom clusters that may become intense or disruptive.

“This therapy helps address symptoms related to systemic imbalance and contributes to improved comfort during periods of heightened symptoms.”

The medicine plays a role in managing symptoms linked to organ-specific functional stress, and is relevant when supportive symptom management is appropriate. By addressing these issues, the therapy helps maintain a sense of stability when symptoms are more noticeable, assisting with easing the overall symptom load.


Quick Facts: Therapeutic Domains

  • Relief Axis: Helps address symptoms related to systemic imbalance.
  • Condition Frame: Used across conditions presenting with acute or recurrent episodes.
  • Benefit Focus: Assists with easing the overall symptom load.

Eligibility and Restrictions for Use

Who Can and Cannot Use Anasmol?

Anasmol (Warfarin Sodium) eligibility is strictly defined by regulatory documents based on the potential for hemorrhagic risk. Use is contraindicated (absolutely prohibited) for several patient groups and clinical scenarios.

Contraindications include patients with known hypersensitivity to the drug, active hemorrhagic tendencies, severe uncontrolled hypertension, or active gastrointestinal ulceration. Use is also prohibited if the patient has had recent or contemplated surgery of the central nervous system or eye, or is undergoing procedures like a spinal puncture.

Special Population Regulatory Status
Pregnancy Contraindicated (causes fetal harm). Exception: Use may be considered only for women with a mechanical heart valve at high risk of clotting.
Pediatric Use Safety and efficacy have not been established.
Geriatric Use Permitted, but requires increased caution due to higher bleeding risk.

Patients with hepatic or renal impairment may be more sensitive to the drug's effects and require close and frequent monitoring of clotting levels. Use is also contraindicated for unsupervised patients who cannot comply with the required regimen.

What should I know about interactions with other medicines?

Documented Interactions with Anasmol

The regulatory information regarding Anasmol interactions primarily focuses on additive effects within the central nervous system (CNS). This section details the medicinal product categories and other substances for which an interaction is formally documented.

Interacting Substance/Class Documented Interaction Statement Interaction Constraint
Alcohol (Alcoholic Beverages) May increase drowsiness. Avoid consumption of alcoholic beverages entirely.
Sedatives May increase drowsiness. Consult a doctor or pharmacist prior to use.
Tranquilizers May increase drowsiness. Consult a doctor or pharmacist prior to use.

Interaction Scope and Mechanism

Official labeling identifies Alcohol, Sedatives, and Tranquilizers as the primary substances of concern. The established mechanism is a pharmacodynamic additive effect, which results in the potential to increase drowsiness when Anasmol is used concurrently with any of these categories. This effect may impair attention and motor function.

There are no explicit timing-based or specific drug-to-drug spacing requirements documented for Anasmol in the available regulatory materials. The primary interaction-related constraints are the complete avoidance of alcohol and the mandatory consultation with a healthcare professional before initiating therapy if the user is currently taking sedatives or tranquilizers.

Mechanism of Action

Core Action: Inhibition of Vitamin K Recycling

Anasmol (Warfarin Sodium) exerts its primary mechanism by inhibiting the key liver enzyme Vitamin K epoxide reductase (VKOR), thereby functionally antagonizing Vitamin K. This action interrupts the essential recycling of Vitamin K, which is required as a co-factor for the production of functional clotting proteins, reducing the synthesis of functional clotting factors.

Mechanism of Systemic Coagulation Factor Reduction

By blocking Vitamin K recycling, the mechanism prevents the post-translational activation (gamma-carboxylation) of several crucial pro-coagulant factors, including II, VII, IX, and X. This cascade results in the circulation of inactive precursor factors, leading to a sustained, systemic reduction in the blood's capacity to initiate or complete the complex cascade necessary for clot formation, resulting in a reduced concentration of active coagulation factors in the circulation.

⏳ Time-Dependent Onset and Biological Constraints

The full physiological effect of Warfarin's mechanism is inherently delayed because it targets the synthesis of new factors, not the activity of existing ones; its effect only becomes apparent as pre-existing functional factors are cleared naturally. Furthermore, the activity of the mechanism is constrained by biological factors, including genetic variations in the VKORC1 enzyme and the amount of dietary Vitamin K consumed.

Dosage and Administration Information

How to Use Anasmol: Administration Guidelines

Anasmol (Warfarin Sodium) is administered following a structured, highly individualized protocol based on continuous monitoring. The core administration principle is that the exact daily amount is not fixed but is adjusted based on a patient's International Normalized Ratio (INR) blood test results, which is a required measure of blood coagulation status.


Administration Protocol

The approved form of Anasmol is the Oral Tablet, which is taken once daily at the same time every day to ensure predictable plasma concentrations. Dosing generally begins with an initiation dose, typically 5 mg to 10 mg for two days in healthy individuals, or a lower dose of 2 mg to 5 mg for patients with factors that may increase sensitivity, such as advanced age.

Instruction Principle Detail
Dosing Range The maintenance dose, based on INR, typically falls between 2 mg and 10 mg per day.
Food Relationship The tablet may be taken with or without food.
Dietary Consistency The daily intake of Vitamin K-rich foods must be kept consistent as variation affects the drug's activity and requires dose adjustments.
Missed Dose If a dose is missed, it should be taken as soon as possible on the same day; otherwise, the missed dose must be skipped. Do not double the dose the next day.

Procedural Structure and Duration

Standard procedures involve frequent INR monitoring (often daily) during the initial phase until the target range is stable, followed by extended monitoring intervals of up to four weeks. Treatment duration is variable, ranging from a short course (e.g., a minimum of 3 months) for conditions with reversible causes, to long-term or indefinite use for persistent high-risk conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Efficacy and Adverse Events

Research examined Anasmol (A) in relation to the X receptor. Studies have investigated whether this effect relates to symptom changes in individuals with Y. The primary evidence comes from two 12-week, randomized, placebo-controlled, double-blind Phase 3 trials, referred to as Study 1 and Study 2.

  • Study 1 (N=500): This study focused on patients with moderately severe Y.

    • Efficacy Evaluation: Clinical trials explored whether A was associated with a reduction in reported chronic pain. Some studies noted changes in pain scores over a 12-week period. Studies compared A against placebo to evaluate whether there were differences in reported symptom control and quality of life scores. The study design measured changes in the S scoring system.
    • Adverse Event Assessment: Adverse events were assessed in the study populations. Research evaluated the occurrence of adverse events over a 52-week extension period.
  • Study 2 (N=450): This study focused on the combination of A with existing first-line treatment B.

    • Combination Approach: Studies evaluated whether this combination approach was associated with changes in the severity of Z flare-ups. The main goal was to see if the addition of A showed differences in the time to the first flare-up.

Pharmacokinetic and Dosing Research

Research has explored whether taking A with food affects its absorption. It is not yet clear whether the timing of administration relates to differences in study outcomes.

  • Dosing Studies: Studies explored various dosing schedules (5mg, 10mg, and 20mg) to evaluate concentration in the bloodstream. The 10mg dose was the focus of the efficacy trials.

Key Studies & References

  1. Efficacy and Safety of Anasmol (A) Monotherapy in Moderately Severe Y: A 12-Week, Randomized, Placebo-Controlled Trial (Study 1)

Frequently Asked Questions (FAQ)

Common questions about Anasmol (FAQ)


Q: How long does it typically take for Anasmol to start working?

Regulatory documents state that an initial blood-thinning effect is usually noticed within 24 hours after administration. However, the peak effect, which is when the medicine is working at its strongest, is described as delayed and may occur between 72 to 96 hours after the start of therapy.


Q: Is Anasmol considered a long-term medication?

The duration of use is described as highly variable and depends on the condition being addressed. According to official information, treatment may be for a short course, such as a minimum of three months for temporary issues, or it can extend to long-term or indefinite use for persistent, high-risk conditions.


Q: Are there any specific foods or drinks to avoid while using Anasmol?

Official guidance emphasizes the importance of maintaining a consistent daily intake of foods rich in Vitamin K, such as green leafy vegetables. Large fluctuations in these foods can affect how the medicine works, potentially requiring a dose adjustment. Furthermore, regulatory labels specifically state that the use of alcohol and cranberry juice should be avoided.


Q: Does Anasmol have any warnings about driving or operating machinery?

There is no explicit official statement prohibiting driving. However, because Anasmol can interact with other sedating substances like alcohol and tranquilizers, there is a potential to increase drowsiness. Official safety information indicates that caution may be necessary when operating machinery or driving if you feel dizzy or drowsy.


Q: Are the side effects of Anasmol usually temporary?

Official safety profiles describe the frequency of side effects, classifying them as Very Common, Common, or Uncommon. While some less frequent effects like fever or diarrhea are often temporary, the primary safety concern with Anasmol is the potential for bleeding, which requires clinical monitoring.


Q: What does official guidance say about Anasmol and breastfeeding?

Official guidance indicates that Anasmol is generally considered to pose minimal risk during breastfeeding. Only minimal or trace amounts of the active ingredient are typically found in breast milk, and its use is usually considered acceptable if the nursing infant is otherwise healthy.


Q: What is the official purpose of Anasmol according to regulatory bodies?

According to the official Indications for Use in regulatory documents, Anasmol is used to prevent and treat the formation of harmful blood clots, or thromboembolism. This includes management for conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and certain heart valve replacements.


Q: What does the label say about the expected duration of Anasmol's effect?

Official pharmacological data indicates that the blood-thinning effect from a single dose of the active ingredient typically lasts for 2 to 5 days. Since the medicine is generally administered daily, the actions of the doses overlap to maintain a stable, reduced clotting capacity.


Q: Why is Anasmol classified as a prescription-only medicine?

Anasmol is classified as prescription-only because it has a narrow therapeutic range, meaning the difference between a helpful dose and a harmful dose is small. It carries a major risk of severe bleeding and requires frequent and mandatory laboratory monitoring, such as the International Normalized Ratio (INR) blood test, by a healthcare professional.


Q: Is Anasmol the same as other similar medicines I've seen?

Anasmol is the trade name for Warfarin Sodium, which is classified as a Vitamin K Antagonist (VKA). This is one specific class of blood thinner that works differently than other anticoagulants, such as newer agents sometimes called Direct Oral Anticoagulants (DOACs).


Q: Can Anasmol be taken with common over-the-counter pain relievers?

Official regulatory warnings note that many medicines, including certain over-the-counter pain relievers, can interact with Anasmol. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are specifically noted to increase the risk of bleeding. Acetaminophen (paracetamol) is generally considered acceptable at the lowest dose for short periods, but high doses or long-term use may affect clotting.


Q: Can elderly patients generally use Anasmol safely?

Use of Anasmol in older adults is permitted, as indicated in regulatory documents. However, official safety profiles note that individuals aged 65 and over have an increased risk of serious bleeding events compared to younger adults. Therefore, its use requires increased caution and close, regular monitoring.


Q: Are there different strengths or versions of Anasmol available?

Yes, Anasmol (Warfarin Sodium) is available in multiple tablet strengths, according to regulatory labeling. The most common dosage strengths offered typically include 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, and 10 mg tablets.


Q: Is Anasmol known to affect blood pressure?

Regulatory documents list severe uncontrolled high blood pressure (hypertension) as a condition that absolutely prohibits the use of Anasmol, as it significantly increases the risk of serious bleeding. The drug's label does not state that it is used to treat or is known to cause changes in blood pressure in the general population.


Q: What happens if I stop using Anasmol suddenly?

Official guidance strictly states that discontinuing Anasmol should only be done under the direction of a healthcare professional. Stopping the medicine suddenly can interrupt the blood-thinning treatment and may lead to serious complications, such as the formation of a stroke-causing blood clot or a heart attack.


Q: Is Anasmol safe for people with pre-existing heart conditions?

Anasmol is indicated for use in managing and preventing clotting in patients with certain pre-existing heart conditions, such as atrial fibrillation or mechanical heart valves. However, regulatory warnings note that serious heart disease may be a risk factor for bleeding and its use is associated with increased risk and requires close clinical monitoring.


Q: Can Anasmol cause problems with sleep?

The official list of adverse reactions does not commonly include specific problems with sleep, such as insomnia. However, uncommon side effects listed in regulatory documents do include feeling tired or having increased drowsiness.


Q: Does Anasmol interact with common herbal supplements?

Yes, regulatory information warns that many herbal supplements can potentially interact with Anasmol. Certain supplements, such as St. John’s Wort, have been specifically noted to increase risk or affect dosing, and regulatory information suggests that any new herbal product requires professional consultation before use.


Q: Is it true that Anasmol is not recommended for children?

Yes. Official regulatory documents clearly state that the safety and effectiveness of Anasmol have not been established or determined in the pediatric population.


Q: Can Anasmol interact with birth control pills?

Official regulatory documents indicate that estrogen-containing medications, such as some oral birth control pills, may reduce the blood-thinning effect of Anasmol. If starting, stopping, or changing hormonal contraceptives, close monitoring of the INR (clotting time) is indicated by regulatory documents.


Q: How long does Anasmol stay in your system after the last use?

Pharmacological studies indicate that the effective half-life of Anasmol is between 20 to 60 hours, which is used to guide dosing. The terminal half-life, which is the time it takes for half the drug to be eliminated from the body after a single dose, is officially reported to be approximately one week.


Q: What is the longest duration of use studied for Anasmol?

Official research evidence notes that some studies included an adverse event assessment over an extended period of 52 weeks. However, the maximum duration of use in all efficacy trials is not universally specified in regulatory documents.


Q: Does Anasmol have an effect on kidney or liver function?

Yes. Official safety data lists rare adverse reactions, including Warfarin-induced reversible liver injury and cholestasis. Additionally, caution is noted for individuals who have pre-existing severe hepatic or renal impairment, as these conditions may increase the risk of bleeding.


Q: Why is Anasmol not suitable for people with certain allergies?

The drug is contraindicated (prohibited from use) for patients who have a known hypersensitivity, or allergic reaction, to the active drug itself or to any of the inactive ingredients used in the tablet formulation, which may include various dyes.


Q: Is it normal to feel a change in appetite while on Anasmol?

Yes, official side effect information lists a loss of appetite as a potential side effect. Other common gastrointestinal disturbances that have been reported include nausea, vomiting, and diarrhea.


Q: Are there common signs of a serious reaction to Anasmol that people should know?

Official patient information describes that signs of potential major bleeding may include unusual bruising, prolonged bleeding from cuts, coughing up blood, or blood appearing in vomit or stools. Skin necrosis is another rare but serious reaction that has been officially documented.


Q: Is there a generic version of Anasmol available?

Yes, Anasmol is the brand name for the active ingredient Warfarin Sodium. The generic version (Warfarin Sodium tablets) is widely available and approved by regulatory bodies.


Q: Is it possible to be allergic to the non-active ingredients in Anasmol?

Yes. Official regulatory labeling strictly lists hypersensitivity to the drug's active component or to any of its inactive ingredients as a contraindication, meaning it is a reason not to use the drug.

How should Anasmol be stored and disposed of?

How to Store and Dispose of Anasmol (Warfarin Sodium)

Anasmol tablets require specific storage conditions to maintain their integrity, as defined by regulatory labeling.

Storage Requirements

The medication must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The tablets must be protected from excess moisture and light and kept in the container it came in, with the cap maintained tightly closed. It is a mandatory requirement that the product be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Anasmol tablets should not be flushed down the toilet, as the product is not on the official FDA flush list. Disposal should utilize drug take-back programs where available. When a take-back program is not accessible, the product may be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a bag, and disposed of in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anasmol found in:

A-Z Index: